Thyroid Hormone and C-Reactive Protein Serum Concentrations, Disease Severity and Discharge Outcomes of Ischemic Stroke Patients: A Dataset

Publication Type:

Journal Article

Authors:

Adomas Bunevicius; Henrikas Kazlauskas; Nijole Raskauskiene; Vinsas Janusonis; Robertas Bunevicius

Source:

Biomed Data J. , Volume 1, Issue 2, p.13-18 (2015)

Keywords:

C-reactive protein, Ischemic stroke, Neuroprotection, Outcomes, Thyroid hormones

Abstract:

Ischemic stroke remains a serious public health problem, associated with sig­nificant mortality and morbidity. Accurate and timely prognostication of func­tional and patient-oriented outcomes of stroke victims is important for im­proving patient outcomes and for optimized use of healthcare resources. A growing body of evidence suggests that the Hypothalamic-Pituitary-Thyroid axis hormones can exert neuro-protective properties under ischemic condi­tions and can be employed for outcome prediction in severely ill patients, in­cluding stroke victims. The goal of the present study was to investigate the as­sociation of the HPT-axis and C-reactive protein (CRP) serum concentrations with clinical stroke severity and with functional and cognitive discharge out­comes. Here we present a dataset from prospective observational cohort study of 88 acute ischemic stroke patient admitted within 24 hours after stroke symptom onset and without thyroid gland disorders. All patients received treatment according to the existing guidelines. The dataset includes socio-de­mographic and clinical characteristics, clinical stroke severity assessment (Scandinavian Stroke Scale), serum concentrations of tri-iodothyronine, thy­roxin, thyroid stimulating hormone and CRP that were evaluated within 24 hours after hospital admission. Functional outcome (modified Rankin scale) and cognitive outcome (Mini Mental State Examination) assessments were performed at hospital discharge.

Interested readers can download both the paper and the dataset it describes below, under the respective Creative Commons licence.

Full text: 

Thyroid Hormone and CRP Serum Concentrations, and Outcomes of Ischemic Stroke Patients
The world health report 2007: a safer future: global public health security in the 21st century [Internet]. Geneva, Switzerland: The World Health Organization, WHO Press; 2007 . http://www.who.int/whr/2007/en
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. Geneva, Switzerland: WHO Press; 2014;129:399-410.
Rousseau H, Joffre J, Puel J, Imbert C, Puech JL, Duboucher C, Wallsten H. Percutaneous vascular stent: experimental studies and preliminary clinical results in peripheral arterial diseases. Int Angiol. 1987;6(2):153-61.
Jickling GC, Sharp FR. Blood Biomarkers of Ischemic Stroke. Neurotherapeutics. 2011;8(3):349 - 360.
Adomas B, Hong Y, Weili L. The Potential Roles of 18F-FDG-PET in Management of Acute Stroke Patients. BioMed Research International. 2013;2013:1 - 14.
Bunevicius A, Kazlauskas H, Raskauskiene N, Mickuviene N, Ndreu R, Corsano E, Bunevicius R. Role of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein, and Inteleukin-6 in Predicting a Poor Outcome after a Stroke. Neuroimmunomodulation. 2015;.
Bunevicius A, Iervasi G, Bunevicius R. Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders. Expert Review of Neurotherapeutics. 2015;15(3):315 - 326.
Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. Journal of Endocrinology. 2010;205(1):1 - 13.
Farwell AP. Nonthyroidal illness syndrome. Current Opinion in Endocrinology & Diabetes and Obesity. 2013;20(5):478 - 484.
Leonard JL, Koehrle J. Intracellular pathways of iodothyronine metabolism. Philadelphia, Pennsylvania , USA: Lippincott-Raven Publishers; 1996.
Bunevicius R, Prange AJ. Thyroid disease and mental disorders: cause and effect or only comorbidity?. Current Opinion in Psychiatry. 2010;23(4):363 - 368.
Bianco AC, Salvatore D, Gereben B, Berry MJ, P Larsen R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38-89.
Lin H-Y, Davis FB, Luidens MK, Mousa SA, Cao JH, Zhou M, Davis PJ. Molecular Basis for Certain Neuroprotective Effects of Thyroid Hormone. Frontiers in Molecular Neuroscience. 2011;4.
Leonard JK. Intracellular pathways of iodothyro-nine metabolism. In Werner I, ed. The thyroid: A fundamental and clinical text . 7thth ed. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 136-73.
Ambrosius W, Kazmierski R, Gupta V, A. Warot W, Adamczewska-Kociałkowska D, Błazejewska A, Ziemnicka K, Nowinski WL. Low Free Triiodothyronine Levels are Related to Poor Prognosis in Acute Ischemic Stroke. Experimental and Clinical Endocrinology & Diabetes. 2011;119(03):139 - 143.
Alevizaki M, Synetou M, Xynos K, Pappa T, Vemmos KN. Low triiodothyronine: a strong predictor of outcome in acute stroke patients. Eur J Clin Invest. 2007;37(8):651-7.
Genovese T, Impellizzeri D, Ahmad A, Cornelius C, Campolo M, Cuzzocrea S, Esposito E. Post-ischaemic thyroid hormone treatment in a rat model of acute stroke. Brain Research. 2013;1513:92 - 102.
Zhang Y, Meyer MA. Clinical Analysis on Alteration of Thyroid Hormones in the Serum of Patients with Acute Ischemic Stroke. Stroke Research and Treatment. 2010;2010:1 - 5.
Neidert S, Katan M, Schuetz P, Fluri F, Ernst A, Bingisser R, Kappos L, Engelter ST, Steck A, Müller B, Christ-Crain M. Anterior pituitary axis hormones and outcome in acute ischaemic stroke. Journal of Internal Medicine. 2011;269(4):420 - 432.
Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HCA, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36(6):1316-29.
Hertog HM, Rossum JA, Worp HB, Gemert HMA, Jonge R, Koudstaal PJ, Dippel DWJ. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. Journal of Neurology. 2009;256(12):2003 - 2008.
van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab. 1990;71(6):1567-72.
Abo-Zenah HA, Shoeb SA, Sabry AA, Ismail HA. Relating circulating thyroid hormone concentrations to serum interleukins-6 and -10 in association with non-thyroidal illnesses including chronic renal insufficiency. BMC Endocrine Disorders. 2008;8(1):1.
Jublanc C, Bruckert E, Giral P, Chapman MJ, Leenhardt L, Carreau V, Turpin G. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis. 2004;172(1):7-11.
Lindenstrom E, Boysen G, Christiansen LW, Hansen BR, Nielsen PW. Reliability of Scandinavian Neurological Stroke. Cerebrovasc Dis. 1991;1:103-7.
Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497-500.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
Kazlauskas H, Bunevicius A, Raskauskiene N, Anskoliene A, Radziuviene R, Janusonis V. Cognitive Outcomes of Acute Ischemic Stroke Pa-tients: Association with Concentrations of Thyroid Axis Hormones and C-Reactive Protein. Annals of Neurology. 2012;72(Suppl. 16):S4-S4.
Kazlauskas H, Bunevicius A, Raskauskiene N, Radziuviene R, Anskoliene A, Janusonis V. Functional outcome of acute ischemic stroke pa-tients: association with concentrations of thyroid hormones and C-reactive protein. European Journal of Neurology. 2012;(Suppl 1):152.
Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R. Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study. Endocrine. 2014;45(2):213 - 220.
National Library of Medicine (brackets, no "et al."): Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R. Thyroid Hormone and C-Reactive Protein Serum Concentrations, Disease Severity and Discharge Outcomes of Ischemic Stroke Patients: A Dataset. Biomed Data J. . 2015;1(2):13-18.
National Library of Medicine (grant proposals with PMCID/PMID): Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R. Thyroid Hormone and C-Reactive Protein Serum Concentrations, Disease Severity and Discharge Outcomes of Ischemic Stroke Patients: A Dataset. Biomed Data J. . 2015;1(2):13-18.
National Library of Medicine (NLM) - Grant with PMID: Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R. Thyroid Hormone and C-Reactive Protein Serum Concentrations, Disease Severity and Discharge Outcomes of Ischemic Stroke Patients: A Dataset. Biomed Data J. . 2015;1(2):13-18.
I acknowledge that I have read, understand, and accept these conditions for using the dataset(s).
22,035 times
# File Name Number of Downloads
1 bmdj.01204_Thyroid_Hormone_Ischemic_Stroke.pdf 4060
2 01204_Stroke_Bunevicius.ods 1842
3 01204_Stroke_Bunevicius.xlsx 1542
(2)
Share